Increased Availability of COVID-19 Therapeutics
March 31, 2022
Throughout Orange County, rates of SARS-CoV-2 infection appear to be leveling off after declining for several weeks. The Omicron BA.2 sub-variant has been increasing in prevalence as cases decline.
 
Yesterday, the California Department of Public Health (CDPH) released a Health Alert (CAHAN) providing updated information on the status of therapeutics for COVID-19 disease. The key point of this CAHAN is that there is no longer limited supply of therapeutic treatments in most locations.
Clinical Updates
As of this writing, all outpatients with mild to moderate COVID-19 who are at high risk for disease progression should be offered treatment if eligible based on the product Emergency Use Authorizations (EUAs). Treatment should be offered regardless of vaccination status. Because of the predominance of the Omicron sub-variant BA.2, sotrovimab is no longer authorized for use in California.
 
The Health and Human Services’ (HHS) COVID-19 Therapeutics Locator tool lists pharmacy locations and infusion centers that have received shipments of federally-procured Covid-19 therapeutic agents and have reported available treatment courses in the last 7 days. Prescribers should refer to this tool when writing prescriptions for outpatient COVID-19 treatments.
 
The US federal government recently announced a new Test to Treat initiative; Test to Treat sites can both test for SARS-CoV-2 and dispense COVID-19 treatments. Current sites participating in the federal program can be found on the new HHS Test to Treat Locator, which went live on 3/30/2022.
 
Additional Resources
Contact Information
For questions or concerns, providers can contact the OCHCA Communicable Disease Control Division at 714-834-8180.